Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this study is to determine whether therapy with rituximab alters the immune response in relapsed or refractory, low-grade or follicular, CD20+, B-cell NHL subjects in comparison to untreated, age-matched control subjects. The primary endpoint of the study is to determine whether treatment with rituximab causes a clinically significant effect on immunological recall response to tetanus vaccine in NHL subjects.
Critère d'inclusion
- Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)